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It is well-established that FBXW7 acts as a tumor suppressor
by promoting the polyubiquitylation via the K48 linkage of a
broad range of oncoproteins for proteasome degradation.
We and the others found that FBXW7 also recognizes non-
canonical substrates, such as XRCC4 or γ-catenin for
polyubiquitylation via the K63 linkage, not for degradation,
but for functional modulation. Most recently, we found that
FBXW7 binds to a pseudo-substrate LSD1, not for degra-
dation, rather being self-degraded. Thus, FBXW7 has three
modes of action in a manner dependent of substrates,
leading to different biological consequences.
FBXW7 is an F-box protein, acting as substrate recogni-
tion subunit of SCF (SKP1-CUL1-F-box protein) E3 ubiquitin
ligase complex. It has been well-established that FBXW7
functions as a typical tumor suppressor by targeting a large
number of critical human oncoproteins for ubiquitylation and
proteasome degradation. These oncoprotein substrates
include cyclin E, c-JUN, c-MYC, NOTCH-1, and MCL-1,
among others (Welcker and Clurman, 2008), and most of
these substrates are transcription factors or key signaling
molecules that regulate a wide range of cellular process,
leading to proliferation and tumor progression. It is, there-
fore, not surprising that loss-of-function of FBXW7 by
genomic deletion or mutation, promoter hypermethylation
frequently occurs in various human cancers (Welcker and
Clurman, 2008; Nakayama and Nakayama, 2006; Wang
et al., 2014). Specifically, cholangiocarcinoma and T cell
acute lymphoblastic leukaemias (T-ALL) harbor the highest
mutation rates of FBXW7 up to approximately 30%; Pan-
creatic, gastric, colon carcinomas, prostate and endometrial
cancers had mutation frequencies in the range 4%–15%
(Welcker and Clurman, 2008). And it has been shown that
tissue specific ablation of Fbxw7 accelerated tumorigenesis
in various mouse models (Mao et al., 2004; Zhou et al.,
2013).
In response to a degradation signal, the substrates of
FBXW7 are often phosphorylated by a kinase on the thre-
onine or serine residue within an evolutionarily conserved
motif, designated as CPD (Cdc4 phosphodegron), followed
by FBXW7 binding and subsequent polyubiquitylation by
SCF E3 ligase (Wang et al., 2014). The ubiquitin contains 7
lysine residues (K6, K11, K27, K29, K33, K48 and K63), and
ubiquitin chains assembled to targeted substrates could be
diversely formed through its different linkage on a particular
lysine residue or even formed between the amino group of
methionine residues of ubiquitin and the carboxy group of
glycine residues of another (termed as K0/linear ubiquitin
linkage) (Kirisako et al., 2006), leading to different chains of
topology that determines the fate of the substrates (Ikeda
and Dikic, 2008). Among all ubiquitin chains, the linkage via
K48 and K63 is well-studied and defined. The polyubiquity-
lated substrates via the K48 linkage are readily recognized
by proteasome for targeted degradation, whereas those with
the K63 linkage are not doomed for degradation, rather for
altered functions, such as setting up a platform to facilitate
the recruitment of other proteins in the formation of a func-
tional complex (Ikeda and Dikic, 2008).
Until recent, most known FBXW7 substrates are polyu-
biquitylated via the K48 linkage for proteasome degradation.
Two exceptions were reported from our laboratory and
another laboratory, showing that FBXW7 also recognizes
non-canonical substrates for polyubiquitylation via the K63
linkage (Zhang et al., 2016; Li et al., 2018). Most recently, we
found that FBXW7 binds to a pseudo substrate, LSD1
(lysine-specific demethylase 1) with a surprising conse-
quence: not promoting LSD1 ubiquitylation, rather being self-
ubiquitylated and degraded (Lan et al., 2019). Here, we
summarize the effect of FBXW7 on these non-degradative
substrates and the functional consequence to the substrates
and FBXW7 itself:











We recently found that FBXW7 enhances nonhomolo-
gous end-joining (NHEJ) repair by targeting XRCC4 for
polyubiquitylation via the K63 linkage (Zhang et al., 2016)
(Fig. 1). Mechanistic studies revealed that, upon radiation,
FBXW7 is phosphorylated at the S26 by ATM, and recruited
to DNA damage sites. Radiation also activates DNA-PK to
phosphorylate XRCC4, a core protein involving NHEJ.
FBXW7 meets and binds phosphorylated XRCC4 at the
damage sites on its CPD motif to promote XRCC4 polyu-
biquitylation at the K296 via the K63 linkage, not for degra-
dation, but facilitating recruitment of Ku70/80 heterodimer to
enhance efficiency of NHEJ repair. Moreover, we demon-
strated that UBC13, an E2 that predominantly mediates K63-
linked polyubiquitylation (VanDemark et al., 2001), was
involved in the FBXW7-XRCC4 interaction, and UBC13
knockdown inhibited the NHEJ repair, which further support
the notion that FBXW7 favors the K63 linkage towards
XRCC4. To further elucidate the importance of FBXW7-
XRCC4 interaction in NHEJ repair, several mutants, includ-
ing the ubiquitin-resistant XRCC4-K296R, the recruitment-
deficient FBXW7-S26A, and the phosphorylation-resistant
XRCC4-S325A/S326A were generated, and all mutants
showed significantly reduced NHEJ repair capacity. Biolog-
ically, these FBXW7 mutants are less effective in protecting
cells from radiation-induced damage, as measured by
clonogenic survival assay. Consistently, FBXW7 inactivation
via genetic or pharmacological approach inhibits the NHEJ
repair and sensitizes cancer cells to radiation (Zhang et al.,
2016).
Collectively, we defined that XRCC4 is the first non-
degradative FBXW7 substrate. FBXW7-mediated K63-linked
polyubiquitylation of XRCC4 facilitates the NHEJ repair and
confers radiation protection. The translation implication of
this study is that cancer patients with inactivated FBXW7
might have a better prognosis with radiotherapy.
In last year, another group showed that FBXW7 promotes
K63-linked polyubiquitylation of γ-catenin to suppress cell
proliferation and G2/M cell cycle transition (Li et al., 2018)
(Fig. 1). In that report, the authors found that γ-catenin was a
novel binding partner of FBXW7, whereas the stability of γ-
catenin was not changed by FBXW7 manipulation. Using
three ubiquitin mutants including K11, K48 and K63, FBXW7
was found to specifically promote K63-linked polyubiquity-
lation of γ-catenin. The functional consequence of γ-catenin
polyubiquitylation was demonstrated by an enhanced activity
in transcription of γ-catenin downstream gene 14-3-3σ in a
manner dependent of FBXW7. Biologically, FBXW7
enhanced the function of γ-catenin in its capacity of sup-
pressing cell proliferation and inducing G2/M arrest (Li et al.,
2018).
This study, therefore, uncovered γ-catenin as a new non-
degradative substrate subject to FBXW7-mediated polyu-
biquitylation via the K63 linkage for enhanced function, thus
providing a new mechanism of FBXW7 in negative regula-
tion of cell cycle progression and cell proliferation.
Most recently, we identified LSD1 (also known as
KDM1A) as a pseudo-substrate of FBXW7, which was nei-
ther for targeted degradation, nor for altered function, rather
unexpectedly triggering FBXW7 self-ubiquitylation and sub-
sequent degradation (Lan et al., 2019) (Fig. 1). LSD1 is the
first histone demethylase identified as a transcriptional
repressor to regulate gene expression via catalyzing the
demethylation of mono- and di-methylated histone 3 lysine 4
(H3K4Me1, H3K4Me2) (Shi et al., 2004). Using co-im-
munoprecipitation, we found that FBXW7 directly binds to
LSD1 via the CPD binding sites, but fails to promote LSD1
ubiquitylation nor the protein stability. Surprisingly, FBXW7-
LSD1 binding significantly attenuated FBXW7 binding with
its substrates, such as c-MYC, cyclin E and NOTCH 1
(Welcker and Clurman, 2008), suggesting that the pseudo-
substrate could compete with bona fide substrates for
FBXW7 binding. Furthermore, we found that LSD1 nega-
tively regulates the protein level and half-life of FBXW7 in a
manner dependent of its FBXW7 binding, but independent of
its demethylase activity. Interestingly, LSD1-induced FBXW7
degradation can only be completely rescued by the combi-
nation of inhibitors targeting both proteasome (e.g., MG132)
and lysosome (e.g., CQ, chloroquine), implying that autop-
hagy also plays a role in FBXW7 degradation. Mechanistic
study revealed that LSD1 disrupts FBXW7 dimerization and
accelerates monomeric FBXW7 for self-ubiquitylation, which
is then degraded via both proteasome and p62-mediated
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Figure 1. Non-canonical substrates of FBXW7. 1) FBXW7
binds to XRCC4 and promotes its polyubiquitylation via the K63
linkage, not for degradation, but for facilitating Ku70/80 recruit-
ment to enhance the NHEJ repair; 2) FBXW7 promotes γ-
catenin polyubiquitylation via the K63 linkage to increase the
transcriptional expression of 14-3-3σ, and to enhance the
activity in growth suppression and G2/M arrest; 3) LSD1, a
pseudo-substrate of FBXW7, destabilizes FBXW7 by disrupting
its dimerization and triggering its self-ubiquitylation for degra-
dation via both proteasome and lysosome pathways.
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abrogates FBXW7 functions in growth suppression, NHEJ
repair and radiation protection (Lan et al., 2019).
Collectively, we identified LSD1 as a FBXW7 pseudo-
substrate, which is not being ubiquitylated or degraded, but
triggers FBXW7 self-ubiquitylation and degradation. We,
therefore, established a novel demethylase-independent
oncogenic mechanism of LSD1 via targeting FBXW7. Our
study provided a novel strategy to reactivate FBXW7 in
human cancer with LSD1 overexpression via targeting LSD1
protein for degradation, rather than merely inhibiting its
enzymatic activity (Lan et al., 2019).
Taken together, the studies described here reveal that
FBXW7 not only targets a number of oncogenic proteins for
degradation, but also regulate protein functions via K63-
linked polyubiquitylation. Furthermore, FBXW7 itself is sub-
jected to negative regulation by its pseudo-substrate, LSD1,
leading to its inactivation (Fig. 1). The identification and
characterization of these non-degradative substrates largely
extends the mechanism of FBXW7 action as a tumor
suppressor.
ACKNOWLEDGEMENTS
This work is supported by the National Key R&D Program of China
(2016YFA0501800) (YS), the National Natural Science Foundation
of China (Grant No. 81572718) (YS).
COMPLIANCE WITH ETHICS GUIDELINES
Huiyin Lan and Yi Sun declare that they have no conflict of interest.
This article does not contain any studies with human or animal
subjects performed by the any of the authors.
OPEN ACCESS
This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
REFERENCES
Ikeda F, Dikic I (2008) Atypical ubiquitin chains: new molecular
signals—protein modifications: beyond the usual suspects review
series. Embo Rep 9(6):536–542
Kirisako T, Kamei K, Murata S, Kato M, Fukumoto H, Kanie M, Sano
S, Tokunaga F, Tanaka K, Iwai K (2006) A ubiquitin ligase
complex assembles linear polyubiquitin chains. EMBO J 25
(20):4877–4887
Lan H, Tan M, Zhang Q, Yang F, Wang S, Li H, Xiong X, Sun Y
(2019) LSD1 destabilizes FBXW7 and abrogates FBXW7 func-
tions independent of its demethylase activity. Proc Natl Acad Sci
USA 116(25):12311–12320
Li Y, Hu K, Xiao X, Wu W, Yan H, Chen H, Chen Z, Yin D (2018)
FBW7 suppresses cell proliferation and G2/M cell cycle transition
via promoting γ-catenin K63-linked ubiquitylation. Biochem Bio-
phys Res Commun 497(2):473–479
Mao JH, Perez-losada J, Wu D, Delrosario R, Tsunematsu R,
Nakayama KI, Brown K, Bryson S, Balmain A (2004) Fbxw7/
Cdc4 is a p53-dependent, haploinsufficient tumour suppressor
gene. Nature 432(7018):775–779
Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle
control and cancer. Nat Rev Cancer 6(5):369–381
Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero
RA, Shi Y (2004) Histone demethylation mediated by the nuclear
amine oxidase homolog LSD1. Cell 119(7):941–953
VanDemark AP, Hofmann RM, Tsui C, Pickart CM, Wolberger C
(2001) Molecular insights into polyubiquitin chain assembly:
crystal structure of the Mms2/Ubc13 heterodimer. Cell 105
(6):711–720
Wang Z, Liu P, Inuzuka H, Wei W (2014) Roles of F-box proteins in
cancer. Nat Rev Cancer 14(4):233–247
Welcker M, Clurman BE (2008) FBW7 ubiquitin ligase: a tumour
suppressor at the crossroads of cell division, growth and
differentiation. Nat Rev Cancer 8(2):83–93
Zhang Q, Karnak D, Tan M, Lawrence TS, Morgan MA, Sun Y (2016)
FBXW7 facilitates nonhomologous end-Joining via K63-linked
polyubiquitylation of XRCC4. Mol Cell 61(3):419–433
Zhou W, Wei W, Sun Y (2013) Genetically engineered mouse
models for functional studies of SKP1-CUL1-F-box-protein (SCF)
E3 ubiquitin ligases. Cell Res 23(5):599–619









Non-degradative substrates of FBXW7 COMMENTARY
